Blaeser Anthony, Awano Hiroyuki, Wu Bo, Lu Qi-Long
McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, 1000 Blythe Blvd., Charlotte, NC 28203, United States of America.
PLoS One. 2016 Oct 6;11(10):e0164187. doi: 10.1371/journal.pone.0164187. eCollection 2016.
Mutations in the gene for fukutin-related protein represent a subset of muscular dystrophies known as dystroglycanopathies characterized by loss of functionally-glycosylated-alpha-dystroglycan and a wide range of dystrophic phenotypes. Mice generated by our lab containing the P448L mutation in the fukutin-related protein gene demonstrate the dystrophic phenotype similar to that of LGMD2I. Here we examined the morphology of the heart and diaphragm, focusing on pathology of diaphragm and cardiac function of the mutant mice for up to 12 months. Both diaphragm and heart lack clear expression of functionally-glycosylated-alpha-dystroglycan throughout the observed period. The diaphragm undergoes progressive deterioration in histology with increasing amount of centranucleation and inflammation. Large areas of mononuclear cell infiltration and fibrosis of up to 60% of tissue area were detected as early as 6 months of age. Despite a less severe morphology with only patches of mononuclear cell infiltration and fibrosis of ~5% by 12 months of age in the heart, cardiac function is clearly affected. High frequency ultrasound reveals a smaller heart size up to 10 months of age. There are significant increases in myocardial thickness and decrease in cardiac output through 12 months. Dysfunction in the heart represents a key marker for evaluating experimental therapies aimed at cardiac muscle.
福金相关蛋白基因的突变代表了一类称为糖基化缺陷型肌营养不良症的肌肉营养不良症,其特征是功能性糖基化的α- dystroglycan缺失以及广泛的营养不良表型。我们实验室培育的携带福金相关蛋白基因P448L突变的小鼠表现出与LGMD2I相似的营养不良表型。在此,我们检查了心脏和膈肌的形态,重点关注突变小鼠膈肌的病理学和心脏功能,观察时间长达12个月。在整个观察期内,膈肌和心脏均缺乏功能性糖基化的α- dystroglycan的清晰表达。膈肌组织学逐渐恶化,中央核化和炎症增加。早在6个月大时就检测到大面积的单核细胞浸润和纤维化,占组织面积的60%。尽管心脏在12个月大时形态学变化较轻,仅有约5%的单核细胞浸润和纤维化斑块,但心脏功能明显受到影响。高频超声显示,在10个月大之前心脏尺寸较小。在12个月内,心肌厚度显著增加,心输出量减少。心脏功能障碍是评估针对心肌的实验性治疗方法的关键指标。